Efficacy and Safety of Sacubitril/Valsartan in Maintenance Hemodialysis Patients With Heart Failure

Exclusion Criteria

• •Acute renal failure with hemodialysis.
• •Isolated right heart failure owing to pulmonary disease, primary cause of dyspnea due to noncardiac, non-HF causes such as acute or chronic respiratory disorders.
• •Systolic blood pressure lower than 100 mmHg at screening (\<95 mmHg at the randomization visit).
• •Previous history of intolerance to recommended target doses of angiotensin receptor blockers.
• •Significant laboratory abnormalities at screening interfering with assessment of study drug safety or efficacy (such as serum potassium\>5.5 or \<3.5mmol/L, serum sodium\<130mmol/L or alanine aminotransferase or aspartate aminotransferase\>2 times the upper limit of the normal range)
• •History of hypersensitivity to any of the study drugs or their excipients or to drugs of similar chemical classes.
• •History of angioedema.
• •Any medications that have potential for drug-drug interaction with LCZ696 will not be allowed during the study.
• •Pregnant female.
• •Use of sacubitril/valsartan prior to week-2.